SpectronRx, a radiopharmaceutical developer and manufacturer, and RLS (Radioisotope Life Sciences) Inc., a nuclear medicine pharmacy network, entered an agreement designed to enhance the supply and availability of diagnostic and therapeutic radiopharmaceuticals. The companies aim to further bridge the gap between drug development, manufacturing, distribution, and patient care by improving production and increasing the availability of medicines. 

As part of the agreement, SpectronRx will manufacture radiopharmaceutical products for RLS and other partners, and RLS will distribute them. SpectronRx will utilize RLS’s extensive radiopharmacy network and abundant manufacturing space to develop the products in bulk, after which RLS will prepare the units into patient-, organ-, and time-specific individual doses and deliver them to care providers locally when needed. SpectronRx will also provide services related to the manufacture and distribution of the products, including quality control and testing and regulatory compliance services.

“Radiopharmaceuticals are essential to diagnosing and treating diseases ranging from cancer to neurodegenerative disorders,” said SpectronRx CEO John Zehner. “However, patient access can be limited due to the complex nature of providing these materials. Our partnership with RLS – a one-stop-shop for seamless distribution which sets the standard in quality as the only nationwide radio pharmacy network to have received The Joint Commission Gold Seal of Approval – will allow us to increase the availability of radiopharmaceutical options for patients and healthcare providers nationwide.”

“This partnership with SpectronRx is a win for patient care,” said RLS CEO Stephen Belcher. “Our collaboration will not only help RLS expand our extensive, accredited network of radio pharmacies into oncology, it will also improve access to novel, life-saving radioisotope-based medicines, which are vital in delivering precision medicine solutions for patients everywhere.”

In addition to enhancing the supply of diagnostic and therapeutic radiopharmaceuticals, the partnership also offers opportunities for innovation through research and development projects, in which both companies will collaborate on new products and processes. This joint effort will help further advance treatments available for patients needing nuclear medicine services.

SpectronRx has three specialties: Radiopharmaceutical Contract Development (rCDMO), Radiopharmaceutical Contract Manufacturing (rCMO), and Isotope Production. Its rCDMO services inlcude drug development, quality assurance (QA) and regulatory services for therapeutic and diagnostic radiopharmaceuticals from conception to FDA and EMA approval much more quickly. The company also produces and manufactures rare medical radioisotopes like actinium-225.